Last edition
News about "ESMO 2026"
Insilico Medicine to Present ISM6331 Phase 1 Data at ESMO 2026
Insilico Medicine will present phase 1 data for Artificial Intelligence (AI)-designed pan-TEAD inhibitor ISM6331 at ESMO 2026 in mesothelioma and advanced solid tumors.
ESMO 2026 | 28/07/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members